The effect of
Iliparcil, a new orally active
beta-D-xyloside venous antithrombotic, was studied on the rethrombosis following
thrombolytic therapy in rats, using a modified Umetsu model. The
drug was administered by oral route prior to
thrombolytic therapy, which consisted of administering a combination of
heparin and
urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively. Time to reocclusion increased from 3.9 min with saline to 10.5 min following H/U injection. When
Iliparcil (30 mg/kg, oral route) was administered 4 h before H/U injection, the time to reocclusion was increased by 250% compared with H/U alone (p < 0.001). Similarly,
dermatan sulfate (DS), administered intravenously (3 mg/kg) 5 min before
thrombus induction, also increased the time to reocclusion (300% compared with H/U alone; p < 0.001). It was also shown that times to reocclusion following
Iliparcil or DS treatments were still increased even when
heparin dosage was decreased. These results suggest that an antithrombotic product derived from the
beta-D-xyloside family could be advantageously used in combination with thrombolytic treatment instead of
heparin, which causes complications and side effects.